Cassava Sciences, Inc. (SAVA)

NASDAQ: SAVA · IEX Real-Time Price · USD
21.93
-0.58 (-2.58%)
At close: Feb 23, 2024, 4:00 PM
21.83
-0.10 (-0.46%)
After-hours: Feb 23, 2024, 7:56 PM EST
-2.58%
Market Cap 926.26M
Revenue (ttm) n/a
Net Income (ttm) -95.43M
Shares Out 42.24M
EPS (ttm) -2.29
PE Ratio n/a
Forward PE 18.59
Dividend n/a
Ex-Dividend Date n/a
Volume 436,006
Open 22.16
Previous Close 22.51
Day's Range 21.80 - 22.31
52-Week Range 12.32 - 32.10
Beta -0.39
Analysts Strong Buy
Price Target 124.00 (+465.44%)
Earnings Date Mar 5, 2024

About SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 26
Stock Exchange NASDAQ
Ticker Symbol SAVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for SAVA stock is "Strong Buy" and the 12-month stock price forecast is $124.0.

Price Target
$124.0
(465.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

NEW YORK, Feb. 24, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and O...

1 day ago - PRNewsWire

CASSAVA SCIENCES INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in Cassava Sciences stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi ...

4 days ago - PRNewsWire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and O...

9 days ago - PRNewsWire

CASSAVA SCIENCES SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in Cassava Sciences stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi ...

9 days ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action...

10 days ago - PRNewsWire

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK , Feb. 11, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed aga...

14 days ago - PRNewsWire

CASSAVA SCIENCES SHAREHOLDER ACTION REMINDER

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava Sciences To Contact Him Directly To Discuss Their Options If you suffered losse...

16 days ago - PRNewsWire

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA

NEW YORK , Feb. 8, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences...

17 days ago - PRNewsWire

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study of simufilam, an in...

18 days ago - GlobeNewsWire

3 small-cap biotechs with potential breakthroughs in 2024

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

Other symbols: AMLXPBYI
19 days ago - MarketBeat

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDA...

20 days ago - Business Wire

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK , Feb. 5, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed agai...

20 days ago - PRNewsWire

Cassava Sciences (SAVA) stock: Is it a buy as short-squeeze eases?

Cassava Sciences (NASDAQ: SAVA) stock price has surged hard in the past few months, stinging short-sellers who benefited as it plunged for most of 2023. The shares have surged by more than 106% from t...

5 weeks ago - Invezz

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of wa...

7 weeks ago - GlobeNewsWire

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warrants to holders of ...

2 months ago - GlobeNewsWire

High short interest stocks: this popular trend is re-emerging

The overall markets have been on a tear lately, set to close the year off in style, near their 52-week highs. The popular S&P 500 ETF, the SPDR ETF Trust NYSE: SPY, made a new 52-week high last week a...

Other symbols: ENVXKSS
2 months ago - MarketBeat

Cassava Sciences Appoints Three New Members to its Board of Directors

Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of expe...

2 months ago - GlobeNewsWire

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials.

3 months ago - GlobeNewsWire

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease

AUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to eva...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).   Such investors are advised...

4 months ago - PRNewsWire

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced a potentially significant safety finding based on interi...

4 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Scienc...

4 months ago - Accesswire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Scienc...

4 months ago - Accesswire

Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'

Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigation accused a neuroscientist who often collaborated ...

4 months ago - Market Watch

Cassava Sciences: SAVA stock plot thickens, short interest jumps

Cassava Sciences (NASDAQ: SAVA) stock price will be in the spotlight on Friday after the shares crumbled by over 38% in the extended hours. The shares crashed by more than 76% from the all-time high a...

4 months ago - Invezz